Articles From: Tetra Tech Provides Update on RCM Segment Restructuring to Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)Ezetrol®


Tetra Tech, Inc. (NASDAQ: TTEK) today is providing an update on its previously announced plan to restructure the Remediation and Construction Management (RCM) segment.
Sign-up for Tetra Tech Provides Update on RCM Segment Restructuring investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the third quarter ended June 29, 2014, the declaration of a quarterly dividend and changes to the share buyback program.
Sign-up for Tetra Tech Reports Third Quarter Results, Quarterly Dividend and Changes to Share Buyback investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23 million single-award contract with the U.S. Environmental Protection Agency (EPA) to assess and reduce the human health and ecological risk from contaminated fish, sediments, and water-borne pathogens in fresh and marine waters.
Sign-up for Tetra Tech Wins $23 Million U.S. EPA Water Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year, $23.6 million single-award contract with the U.S. Navy to assess and mitigate environmental impacts from expanded training grounds at the Marine Corps Air Ground Combat Center (MCAGCC) in Twentynine Palms, California.
Sign-up for Tetra Tech Wins $23.6 Million U.S. Navy Environmental Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a five-year Indefinite Delivery-Indefinite Quantity, $30 million contract with the National Institute of Standards and Technology (NIST) to provide engineering services for the NIST Center for Neutron Research (NCNR). Tetra Tech will support the NCNR by providing world-class engineering services, including conceptual design/requirements analysis, and systems design and integration services to support upgrades for scientific instrumentation, procedures, and other NCNR components.
Sign-up for Tetra Tech Wins $30 Million NIST Engineering Services Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded a $64 million contract to provide technical assistance for the Power Africa Transactions and Reform Program funded by the U.S. Agency for International Development.
Sign-up for Tetra Tech Wins $64 Million USAID Power Africa Contract investment picks
Tetra Tech, Inc. (NASDAQ: TTEK) announced today it has been awarded three indefinite delivery indefinite quantity (IDIQ) contracts with the U.S. General Services Administration (GSA). The One Acquisition Solution for Integrated Services (OASIS) contracts are designed as vehicles to address all federal agencies’ needs for a full range of service requirements that integrate multiple professional service disciplines.
Sign-up for Tetra Tech Wins Three GSA OASIS Contracts investment picks
THE WOODLANDS, Texas , July 20, 2014 /PRNewswire/ -- TETRA Technologies, Inc. (TETRA or the Company) (NYSE:TTI) today announced that its majority owned, publicly-traded partnership, Compressco Partners, L.P. (Compressco or the Partnership), has entered into a definitive agreement to purchase all the outstanding shares of Compressor Systems, Inc. (CSI) for $825 million in cash, subject to working capital and other adjustments.
Sign-up for Tetra Technologies, Inc. Announces Agreement By Compressco Partners, L.P. To Acquire Compressor Systems, Inc. investment picks
THE WOODLANDS, Texas , Aug.
Sign-up for TETRA Technologies, Inc. Announces Second Quarter 2014 Results And Revises 2014 Earnings Guidance investment picks
THE WOODLANDS, Texas , July 23, 2014 /PRNewswire/ -- TETRA Technologies, Inc. (TETRA or the Company) (NYSE:TTI) expects to release second quarter 2014 results on Friday, August 8, 2014 , and will host a conference call at 10:30 a.m. ET on that day to discuss the results.
Sign-up for TETRA Technologies, Inc. Announces Second Quarter 2014 Results Press Release And Conference Call Schedule investment picks
MALVERN, Pa., June 24, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (the "Company" ) announced the closing of its previously-announced offering of $47 million aggregate principal amount of its 8% Convertible Senior Notes due 2019 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Notes will bear interest at a rate of 8.00% per annum, payable in cash semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2014.
Sign-up for TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced initiation of patient enrollment in the pivotal portion of its IGNITE 2 Phase 3 clinical trial, a two-part trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI). The company has selected the 200 mg eravacycline oral dose for the pivotal portion of the study after evaluating the positive results from the lead-in portion of the trial.
Sign-up for Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI), support advancement of the trial into its pivotal portion.
Sign-up for Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria.
Sign-up for Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in IGNITE 1, its Phase 3 clinical trial evaluating the safety and efficacy of eravacycline in the treatment of complicated intra-abdominal infections (cIAI). The Company expects to report top-line results from IGNITE 1 in early first quarter 2015.
Sign-up for Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operational highlights for the second quarter ended June 30, 2014.
Sign-up for Tetraphase Pharmaceuticals Reports Second-Quarter 2014 Financial Results investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in two upcoming investor conferences: About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program ( I nvestigating G
Sign-up for Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference on Friday, September 26 th at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at BioCentury’s 2014 NewsMakers in the Biotech Industry Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in the following upcoming conferences: About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program ( I nvestigating G
Sign-up for Tetraphase Pharmaceuticals to Present at Upcoming Conferences investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the annual Wedbush Life Sciences Conference on Wednesday, August 13 at 2:30 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at Wedbush Life Sciences Conference investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that nine posters and one oral presentation on data related to the Company’s next-generation antibiotics portfolio – including its lead candidate eravacycline that is currently in Phase 3 clinical development for treatment of bacterial infections including multidrug-resistant (MDR) infections – will be presented at the upcoming 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The research will highlight: ICAAC 2014 occurs in Washington, DC from September 5 – 9, 2014, at the Walter E.
Sign-up for Tetraphase to Present Research at ICAAC on Its Novel Chemistry Platform’s Ability to Address Antibiotic Resistance investment picks
Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm (EIB) in patients 12 years of age and older.
Sign-up for Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI) investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products.
Sign-up for Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of Generic Baraclude® Tablets, 0.5mg and 1mg, in the United States investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort ® .
Sign-up for Teva Announces UK High Court Gives Positive Judgment in the Company’s Patent Case Against AstraZeneca investment picks
Teva Canada Announces the Launch of (Pr)Teva-Escitalopram, a Generic of (Pr)Cipralex® Canada NewsWire TORONTO , Sept.
Sign-up for Teva Canada Announces the Launch of (Pr)Teva-Escitalopram, a Generic of (Pr)Cipralex® investment picks
2014/9/15
Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)Ezetrol® Canada NewsWire TORONTO , Sept.
Sign-up for Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)Ezetrol® investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Tetra Tech Provides Update on RCM Segment Restructuring to Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)Ezetrol®
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices